康弘药业：截至目前中成药板块的KH110处于临床III期阶段

Group 1 - The core point of the article is that Kanghong Pharmaceutical (002773) has announced that its traditional Chinese medicine product KH110, aimed at treating Alzheimer's disease, is currently in the clinical phase III [1] - The company encourages stakeholders to pay attention to future developments regarding the drug [1] - The article highlights that the outcomes and timelines for drug research, clinical trials, evaluations, and approvals are subject to uncertainty [1]